Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Allegheny Health Network Team Develops Biomarker for Early Detection of Esophageal Cancer
  • USA - English


News provided by

Allegheny General Hospital

Aug 06, 2014, 10:00 ET

Share this article

Share toX

Share this article

Share toX

Blair Jobe MD
Blair Jobe MD

PITTSBURGH, PA (PRWEB) August 06, 2014 -- A research team led by Allegheny Health Network surgical oncologist Blair Jobe, MD, has developed and validated a four-protein serum biomarker panel that holds significant promise for early detection of esophageal cancer, a relatively rare but often deadly disease that has grown in incidence over the past several decades.

Dr. Jobe’s findings were published online today in Cancer, a journal of the American Cancer Society.

"We've made progress in treating and monitoring patients with conditions that can progress to esophageal cancer. Yet only a small minority of these patients develop life-threatening esophageal cancer. Better detection is needed." - Blair Jobe, MD

Post this

The four-protein panel, called B-AMP (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9), is a simple, non-invasive, low-cost blood test, that identified esophageal cancer with a high classification accuracy of 87 percent in the study.

The discovery represents a major step forward in not only early detection but also the management of esophageal cancer, said Dr. Jobe, Director of Allegheny Health Network’s Esophageal and Thoracic Institute. The test is already being used at the Institute in a clinical trial setting to monitor the course of esophageal cancer, providing physicians with guidance on response to therapy or early notification of a recurrence and allowing them to pursue different or more aggressive therapies, if necessary.

“Esophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 percent,” said Dr. Jobe. “We’ve made progress in treating and monitoring patients with conditions that can progress to esophageal cancer, such as Gastroesophageal Reflux Disease (GERD), Barrett’s Esophagus and high-grade dysplasia. Yet only a small minority of these patients develop life-threatening esophageal cancer. Better detection techniques are needed to identify the patients who will likely progress from these precursor lesions to cancer.”

The incidence of esophageal cancer is rapidly rising: up to 600 percent higher than in the 1970s. Survival is better when the disease is detected early, but unfortunately most patients do not sense difficulty swallowing until a tumor is advanced, making the development of biomarkers for the cancer critically important.

“We are excited and very optimistic about how this biomarker panel could be used to help patients, from early detection in at-risk patients, to risk-monitoring for patients with conditions that may lead to esophageal cancer, to monitoring the disease course in patients with cancer, adjusting their surveillance and treatment and potentially extending their lives,” said Ali Zaidi, MD, Director of Research at the AHN Esophageal and Thoracic Institute.

The development of blood-based biomarkers has improved early detection and impacted treatment of cancers such as ovarian and prostate, but development of blood-based esophageal cancer biomarkers has been hampered by the difficulty in identifying a single conserved and universal tracking marker.

Using tissue data from the esophageal cancer progression sequence, biomarkers having known cancer relevance and which are upregulated, were selected for testing in the serum. Followed by novel mathematical modeling, Dr. Jobe’s team was able to combine relevant and strong individual biomarkers into a panel that is accurate and reliable in detecting esophageal cancer.

The team used tissue samples obtained from the Department of Pathology at the University of Pittsburgh, representing patients with Barrett’s Esophagus, high-grade dysplasia and esophageal cancer; for identifying and selecting targets for blood testing using a global proteomics profiling platform. The candidate biomarkers were then tested in blood samples from patients with non-Barrett’s esophagus GERD and esophageal cancer. The findings were validated in an independent but similar cohort assembled at Allegheny Health Network and Roswell Park Cancer Institute in Buffalo.

Out of 3,777 identified tissue proteins, five were shown to have significantly elevated levels in blood of patients with esophageal cancer, as compared to those with non-Barrett’s esophagus GERD, and on mathematical modeling four of those five were shown to have predictive value.

Potential future uses for the protein biomarker assay include screening high-risk patients such as those with obesity and GERD, monitoring disease progression from Barrett’s esophagus to high-risk dysplasia to esophageal cancer, tracking a patient’s response to therapy and enabling therapy tailored to a patient’s individual disease biology and detecting recurrence prior to clinical imaging.

“Dr. Jobe’s research shows the value of our approach to working collaboratively and across the full spectrum of disease,” said David Parda, MD, System Chair, Allegheny Health Network Cancer Institute. “This tour de force research integrates clinical work and advanced biology/informatics to improve prevention, treatment, prognostic and predictive capabilities.”

Researchers from the Academic Medical Center in Amsterdam also participated in the study.

Stephanie Waite, Allegheny General Hospital, http://www.wpahs.org, +1 (412) 330-4434, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.